Mostrar el registro sencillo

dc.contributor.authorGómez Revuelta, Marcos
dc.contributor.authorPelayo Terán, José María
dc.contributor.authorJuncal Ruiz, María
dc.contributor.authorOrtiz-García de la Foz, Víctor
dc.contributor.authorVázquez Bourgon, Javier 
dc.contributor.authorGonzález-Pinto, Ana
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2019-04-02T18:39:19Z
dc.date.available2019-04-02T18:39:19Z
dc.date.issued2018
dc.identifier.issn1461-1457
dc.identifier.issn1469-5111
dc.identifier.urihttp://hdl.handle.net/10902/16085
dc.description.abstractBACKGROUND: Different effectiveness profiles among second-generation antipsychotics may be a key point to optimize treatment in patients suffering a first episode of psychosis to affect long-term outcome. The aim of this study was to compare the clinical effectiveness of aripiprazole, ziprasidone, and quetiapine in the treatment of first episode of psychosis at 3-year follow-up. METHOD: From October 2005 to January 2011, a prospective, randomized, open-label study was undertaken. Two hundred-two first-episode, drug-naïve patients were randomly assigned to aripiprazole (n=78), ziprasidone (n =62), or quetiapine (n=62) and followed-up for 3 years. The primary effectiveness measure was all cause of treatment discontinuation. In addition, an analysis based on the intention-to-treat principle was conducted in the analysis for clinical efficacy. RESULTS: The overall dropout rate at 3 years reached 19.3%. Treatment discontinuation rates were significantly different among treatment groups (aripiprazole=73.08%, ziprasidone=79.03%, and quetiapine=95.16%) (?2=11.680; P=.001). Statistically significant differences in terms of nonefficacy, nonadherence, and side effects were observed among treatment groups along the 3-year follow-up determining significant differences in time to all-cause discontinuation (log-rank=32.260; P=.001). Significant differences between treatments were found in the categories of sleepiness/sedation (?2=9.617; P=.008) and increased sleep duration (?2=6.192; P=.004). No significant differences were found in the profile of extrapyramidal symptoms. Patients on aripiprazole were more likely to be prescribed benzodiazepines. CONCLUSIONS: First-episode psychosis patients on quetiapine were more likely to discontinue treatment due to nonefficacy. Identifying different discontinuation patterns may contribute to optimize treatment selection after first episode of psychosis.es_ES
dc.description.sponsorshipThis work was supported by Plan Nacional de Drogas Research (2005-Orden sco/3246/2004); SENY Fundacio (CI 2005–0308007); Fundacion Marques de Valdecilla (API07/011); and Gerencia Regional de Salud de Castilla y Leon (INT/M/04/17). The study was carried out at the Hospital Marques de Valdecilla, University of Cantabria, Santander, Spain. Unrestricted educational and research grants from AstraZeneca, Pfizer, Bristol-Myers Squibb, and Johnson & Johnson provided support for PAFIP activities. No pharmaceutical industry or institutional sponsors participated in the study design, data collection, analysis, or interpretation of the results.es_ES
dc.format.extent11 p.es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.rights© The Author(s). Published by Oxford University Press on behalf of CINP.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.sourceInt J Neuropsychopharmacol. 2018 Dec 1;21(12):1090-1101es_ES
dc.subject.otherAntipsychotic Agentses_ES
dc.subject.otherSchizophreniaes_ES
dc.subject.otherFirst-Episode Psychosises_ES
dc.subject.otherEffectivenesses_ES
dc.titleLong-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidonees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://dx.doi.org/10.1093/ijnp/pyy082es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1093/ijnp/pyy082
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© The Author(s). Published by Oxford University Press on behalf of CINP.Excepto si se señala otra cosa, la licencia del ítem se describe como © The Author(s). Published by Oxford University Press on behalf of CINP.